• Explore /
  • Poster
  • / Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy.

Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy.

Abstract Poster

Authors

null

Peter D. Zang

City of Hope Comprehensive Cancer Center, Duarte, CA

Peter D. Zang , Przemyslaw Twardowski , Delphine L Chen , Evan Thomas Hall , David Hays , Ian Wilson , Kristin Schmiedehausen , Michael Ferris , William Le , Michael A. Postow , Sumanta Kumar Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Diagnostics and Imaging

Clinical Trial Registration Number

NCT03802123

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 375)

DOI

10.1200/JCO.2024.42.4_suppl.375

Abstract #

375

Poster Bd #

E21

Abstract Disclosures

Similar Posters

First Author: Sumanta Kumar Pal

First Author: Daniel M. Geynisman

First Author: Joseph Vento

First Author: Luis A Meza